Skip to main content

Table 1 p65BTK score of the NSCLC patients’ tissue analyzed by IHC

From: p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

p65BTK expression All (382) AdC (293) SCC (89) Smokers (283) Non-smokers (65)
Negative 189 (49.3%) 129 (43.9%) 60 (67.4%) 151 (53.3%) 18 (27.7%)
1–10% positive cells 131 (34.2%) 106 (36%) 25 (28.1%) 101 (35.7%) 21 (32.3%)
11–20% positive cells 12 (3.1%) 10 (3.4%) 2 (2.2%) 5 (1.8%) 5 (7.7%)
21–50% positive cells 24 (6.3%) 23 (7.8%) 1 (1.1%) 15 (5.3%) 8 (12.1%)
51–100% positive cells 26 (6.8%) 25 (8.5%) 1 (1.1%) 11 (3.9%) 13 (20%)
Positive 193(50.4%) 164 (55.8%) 29 (32.6%) 132 (46.7%) 47 (72.3%)
  1. The analysis was performed on TMA using the antibody BN30, produced and characterized in the lab. AdC adenocarcinoma, SCC squamous cell carcinoma
  2. In bold are indicated the number of samples completely negative or positive (any positivity) for p65BTK expression